Amydis: Funding, Investors & Team (Oct 2026)
Amydis is a privately-held pharmaceutical company focused on developing innovative chemistry to detect diseases that involve the presence of amyloid proteins. Our mission is to develop a universal, non-invasive diagnostic that is faster, more accessible, and more affordable than current tests for diseases with unmet clinical and medical needs. Amydis has a platform of novel compounds that fluoresces when bound to amyloid proteins, thus enabling diagnosis of such diseases. The Company’s most advanced program is targeting the detection of early stage Alzheimer’s disease, a well-known amyloid disease. Other potential development programs include the detection of Parkinson’s disease, Creutzfeldt-Jakob disease (mad cow disease), Pre-eclampsia, TTR Amyloidosis, and Cerebral Amyloid Angiopathy, all of which are associated with the presence of amyloid protein. Amydis offers you and your loved ones the ability to know whether you are at risk for Alzheimer’s or other amyloid-associated diseases. Knowing will allow you and your healthcare professional to make the right decisions.
Amydis has raised $12.1M across 4 funding rounds on record, the most recent an undisclosed round of $3.4M announced in Nov 2023.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Amydis Company Profile and Key Stats
Latest funding round on record: Nov 2023.
Amydis Funding Rounds
1 of 4 rounds was announced without a disclosed amount and is excluded from the total.
Amydis raised $3.0M in a Grant announced in Oct 2021.
6 months later, an undisclosed round of $5.7M was announced in Apr 2022.
4 months later, a Grant was announced in Aug 2022 with no disclosed amount.
1.3 years later, an undisclosed round of $3.4M was announced in Nov 2023.
Amydis Founders and Leadership Team
Contact details for the Amydis team: 1 of 1 has an email address on file.
Start 14-day free trial →Amydis Funding Compared to Other Biotechnology Startups
Amydis' latest round of $3.4M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Amydis in Biotechnology and San Diego
Companies Similar to Amydis
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Amydis Funding FAQs
What does Amydis do?
Amydis is a privately-held pharmaceutical company focused on developing innovative chemistry to detect diseases that involve the presence of amyloid proteins. Our mission is to develop a universal, non-invasive diagnostic that is faster, more accessible, and more affordable than current tests for diseases with unmet clinical and medical needs. Amydis has a platform of novel compounds that fluoresces when bound to amyloid proteins, thus enabling diagnosis of such diseases. The Company’s most advanced program is targeting the detection of early stage Alzheimer’s disease, a well-known amyloid disease. Other potential development programs include the detection of Parkinson’s disease, Creutzfeldt-Jakob disease (mad cow disease), Pre-eclampsia, TTR Amyloidosis, and Cerebral Amyloid Angiopathy, all of which are associated with the presence of amyloid protein. Amydis offers you and your loved ones the ability to know whether you are at risk for Alzheimer’s or other amyloid-associated diseases. Knowing will allow you and your healthcare professional to make the right decisions.
How much funding has Amydis raised?
Amydis has raised $12.1M across 4 rounds on record. The most recent is an undisclosed round of $3.4M announced in Nov 2023.
When did Amydis last raise funding?
Amydis' most recent funding round on record is an undisclosed round of $3.4M, announced in Nov 2023.
Who is the CEO of Amydis?
Stella Sarraf is listed as CEO at Amydis.
Where is Amydis headquartered?
Amydis is based in San Diego, California, United States.
How many employees does Amydis have?
Amydis is in the 11-50 employee band.
How does Amydis' funding compare to other Biotechnology startups?
Amydis' latest round of $3.4M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Amydis Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Amydis is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.